@ANT_ECUADOR No tengo como saber esos datos ya que la solicitud la hago en la DGT online y me ellos la envían a Ecuador. Podrían revisar si existe algún error con mi licencia? Si me confirman que no, yo realizaría una nueva solicitud hoy mismo.
@ANT_ECUADOR buenos días. Llevo meses intentando canjear mi licencia 0924227085 en España y rechazan la solicitud desde Ecuador. Desde la oficina de ANT en Gye me dicen que está TODO correcto con mi licencia y que no entienden por qué desde Quito lo rechazan. Necesito ayuda urg.
@ANT_ECUADOR Gracias por la respuesta. Ya me lo han dicho anteriormente y he revisado que no he puesto la fecha incorrecta. Les ruego que me ayuden con eso porque nadie me da solución y estoy desesperado. Muchas gracias.
Finally, a sham-controlled CTO PCI trial—and it delivers. ORBITA-CTO: small (n=50), but rigor where it matters—blinding, placebo control, symptom-level data. CTO PCI improves angina beyond placebo, with a clear reduction in episodes and more angina-free days. Not prognosis, not hard endpoints, but real symptom benefit—properly measured. #acc26
https://t.co/UgoJVoX87H
@ANT_ECUADOR@LuisE_Aviles@franialto Buenos días. Yo estoy en la misma situación solo que desde Ecuador lo rechazan a pesar de que mi licencia está válida, con puntos completos y sin multas pendientes. Me podrían ayudar por favor? Llevo meses en esto y la necesito urgente por motivos laborales.
Uso racional del láser de excímeros en la intervención coronaria percutánea compleja: más allá del fracaso del balón https://t.co/rX6Wvsphca #recintervcardiol via @RevEspCardiol
Gim et al. (JACC Cardiovasc Interv 2026) published an interesting report that IVI-guided PCI shows "comparable" outcomes to CABG in diabetic patients with LM or 3-vessel disease. A compelling headline. But the methodology deserves scrutiny before this reshapes practice. A thread.
Intravascular Imaging- vs Angiography-Guided Complex PCI: 5-Year Outcomes From a Randomized Trial
In patients with complex coronary artery lesions undergoing PCI, intravascular imaging guidance reduced the risk of a composite of cardiac death, target vessel–related myocardial infarction, or clinically driven target vessel revascularization at median follow-up of 5.3 years, compared to angiography guidance
#Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare
@JACCJournals@ACCinTouch@hvanspall@DrMarthaGulati@AndrewJSauer@iamritu@Hragy@biljana_parapid
https://t.co/6x6qC8mpqj
The 2025 ESC/EACTS guidelines on the management of valvular heart disease have just been released, with an important update: the age threshold for the Heart Team to consider TAVI instead of surgical intervention has been lowered from 75 to 70 years in patients with tricuspid aortic valve anatomy deemed suitable. #ESCCongress https://t.co/QGIlHvfRm4
LAAC in patients with #AFib and at high-risk for stroke undergoing #epAblation resulted in significantly less bleeding compared with oral anticoagulation, based on results from OPTION trial presented at #AHA24. https://t.co/6NcBWurrPa #cvCoag
Hoy culminan nuestros queridos R5 🫀
Gracias por todo el esfuerzo, dedicación y pasión que habéis puesto durante estos 5 años
Os deseamos éxito en vuestras nuevas aventuras profesionales
Siempre os recordaremos!
#FinDeResidencia#OrgulloDeEquipo#SomosMarañón
In this multicenter registry of 10,872 patients undergoing TAVI, baseline ejection fraction was ≤30% in 914 (8.4%) patients. Of them, the left ventricle recovered in 59.5%, including 26.7% patients whose left ventricle function normalized completely.
No recovery was associated with a significant increase in 3-year mortality (adjusted hazard ratio 1.32; p<0.001).
Three variables were associated with a higher likelihood of left ventricle recovery following TAVI: no previous myocardial infarction, estimated glomerular filtration rate >60 mL/min, and mean aortic valve gradient >40 mmHg before TAVI.
Teams caring for patients with severe aortic stenosis and severe left ventricle dysfunction should assess the likelihood of left ventricle recovery following TAVI. This information and its prognostic implications should be discussed with the patients.
Article: https://t.co/q6uvu21crE
Editorial: https://t.co/cdONHjwDiC
Presented today at #ACC24:
In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: https://t.co/3625asvzu8
In a cohort study of 1,116 patients with STEMI undergoing primary PCI, P2Y12 inhibitor pretreatment was not associated with improved MACCEs https://t.co/jMuzYgdL3P @JACCJournals
There is no “it’ll be a quick diagnostic”/“just a left heart cath”/“ill just shoot the cors”. For all trainees, and early careers: Always have an appropriate indication, documentation, discussion and some reservation. Please add additional wisdom..
Something i difnt know - with each successive inflation, a balloon 'grows' - your 3 mm balloon may not be that size after a couple of inflations- nice lecture from yves louvard